PURPOSE: This study aims to evaluate (64)Cu-DOTA-rituximab (PETRIT) in a preclinical transgenic mouse model expressing human CD20 for potential clinical translation. PROCEDURES: (64)Cu was chelated to DOTA-rituximab. Multiple radiolabeling, quality assurance, and imaging experiments were performed. The human CD20 antigen was expressed in B cells of transgenic mice (CD20TM). The mice groups studied were: (a) control (nude mice, n = 3) that received 7.4 MBq/dose, (b) with pre-dose (CD20TM, n = 6) received 2 mg/kg pre-dose of cold rituximab prior to PETRIT of 7.4 MBq/dose, and (c) without pre-dose (CD20TM, n = 6) PETRIT alone received 7.4 MBq/dose. Small animal PET was used to image mice at various time points (0, 1, 2, 4, 24, 48, and 72 h). The OLINDA/EXM software was used to determine the human equivalent dose for individual organs. RESULTS: PETRIT was obtained with a specific activity of 545 ± 38.91 MBq/nmole, radiochemical purity >95%, and immunoreactivity >75%. At 24 h, spleenic uptake of PETRIT%ID/g (mean ± STD) with and without pre-dose was 1.76 ± 0.43% and 16.5 ± 0.45%, respectively (P value = 0.01). Liver uptake with and without pre-dose was 0.41 ± 0.51% and 0.52 ± 0.17% (P value = 0.86), respectively. The human equivalents of highest dose organs with and without pre-dose are osteogenic cells at 30.8 ± 0.4 μSv/MBq and the spleen at 99 ± 4 μSv/MBq, respectively. CONCLUSIONS: PET imaging with PETRIT in huCD20 transgenic mice provided human dosimetry data for eventual applications in non-Hodgkins lymphoma patients.
PURPOSE: This study aims to evaluate (64)Cu-DOTA-rituximab (PETRIT) in a preclinical transgenicmouse model expressing humanCD20 for potential clinical translation. PROCEDURES: (64)Cu was chelated to DOTA-rituximab. Multiple radiolabeling, quality assurance, and imaging experiments were performed. The humanCD20 antigen was expressed in B cells of transgenic mice (CD20TM). The mice groups studied were: (a) control (nude mice, n = 3) that received 7.4 MBq/dose, (b) with pre-dose (CD20TM, n = 6) received 2 mg/kg pre-dose of cold rituximab prior to PETRIT of 7.4 MBq/dose, and (c) without pre-dose (CD20TM, n = 6) PETRIT alone received 7.4 MBq/dose. Small animal PET was used to image mice at various time points (0, 1, 2, 4, 24, 48, and 72 h). The OLINDA/EXM software was used to determine the human equivalent dose for individual organs. RESULTS: PETRIT was obtained with a specific activity of 545 ± 38.91 MBq/nmole, radiochemical purity >95%, and immunoreactivity >75%. At 24 h, spleenic uptake of PETRIT%ID/g (mean ± STD) with and without pre-dose was 1.76 ± 0.43% and 16.5 ± 0.45%, respectively (P value = 0.01). Liver uptake with and without pre-dose was 0.41 ± 0.51% and 0.52 ± 0.17% (P value = 0.86), respectively. The human equivalents of highest dose organs with and without pre-dose are osteogenic cells at 30.8 ± 0.4 μSv/MBq and the spleen at 99 ± 4 μSv/MBq, respectively. CONCLUSIONS: PET imaging with PETRIT in huCD20 transgenic mice provided human dosimetry data for eventual applications in non-Hodgkins lymphomapatients.
Authors: Lin Li; James Bading; Paul J Yazaki; Amitkumar H Ahuja; Desiree Crow; David Colcher; Lawrence E Williams; Jeffrey Y C Wong; Andrew Raubitschek; John E Shively Journal: Bioconjug Chem Date: 2007-11-08 Impact factor: 4.774
Authors: Flavio Forrer; Jianhua Chen; Melpomeni Fani; Pia Powell; Andreas Lohri; Jan Müller-Brand; Gerhard Moldenhauer; Helmut R Maecke Journal: Eur J Nucl Med Mol Imaging Date: 2009-04-07 Impact factor: 9.236
Authors: D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn Journal: N Engl J Med Date: 1978-06-22 Impact factor: 91.245
Authors: Kirstin A Zettlitz; Richard Tavaré; Scott M Knowles; Kristopher K Steward; John M Timmerman; Anna M Wu Journal: Clin Cancer Res Date: 2017-09-19 Impact factor: 12.531
Authors: Richard Tavaré; Melissa N McCracken; Kirstin A Zettlitz; Scott M Knowles; Felix B Salazar; Tove Olafsen; Owen N Witte; Anna M Wu Journal: Proc Natl Acad Sci U S A Date: 2014-01-03 Impact factor: 11.205
Authors: Lemonitsa H Mammatas; Henk M W Verheul; N Harry Hendrikse; Maqsood Yaqub; Adriaan A Lammertsma; C Willemien Menke-van der Houven van Oordt Journal: Cell Oncol (Dordr) Date: 2014-09-24 Impact factor: 6.730
Authors: Chirag B Patel; Sindhuja Ramakrishnan; Arutselvan Natarajan; Paramjyot S Panesar; Steven R Long; Sanjiv S Gambhir Journal: Clin Cancer Res Date: 2018-10-29 Impact factor: 12.531